The Future of 340B: New Bills Offer Competing Solutions to Modernize the 340B Drug Discount Program

Short summary

Two competing bills—H.R. 9599 (SECURE 340B Act) in the House and a Senate discussion draft from Sen. Cassidy—propose the first comprehensive updates to the 340B drug discount program since 1992. The House bill defines a new patient eligibility standard, delays rebate models for four years, and mandates a third-party clearinghouse for claims data. Both bills address contract pharmacy oversight, transparency, and accountability concerns that have grown around the program.

• •House H.R. 9599 and Senate draft offer competing 340B modernization frameworks
• •House bill introduces new patient definition, delays rebate model transition, and requires HHS-contracted clearinghouse
• •Both bills target contract pharmacy oversight and transparency gaps

Generated with AI, which can make mistakes.